Dimericon Therapeutics

Dimericon Therapeutics is a private biotech developing crosslinked helix dimer mimetics ("Dimericons") to target hard-to-drug intracellular protein–protein interactions and to serve as templates for small-molecule development. The company is advancing a lead program toward IND-enabling preclinical studies for hematological malignancies following a Seed financing round.